% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Desaulniers:298581,
      author       = {M. Desaulniers and É. Rousseau and K. M. Pabst$^*$},
      title        = {{C}linical and {R}esearch {A}pplications of {FAPI}
                      {T}racers: {A} {R}eview.},
      journal      = {BJR},
      volume       = {nn},
      issn         = {0007-1285},
      address      = {Oxford},
      publisher    = {Oxford University Press},
      reportid     = {DKFZ-2025-00298},
      pages        = {nn},
      year         = {2025},
      note         = {epub},
      abstract     = {In the last decade, fibroblast activation protein-α
                      inhibitors (FAPIs), which target the cancer-associated
                      fibroblasts of the tumour microenvironment, have become a
                      topic of great interest. In oncology, FAPI PET/CT imaging
                      has repeatedly demonstrated a higher lesion detection rate
                      than other conventional imaging modalities such as CT or
                      18F-FDG PET/CT for several tumours. In some cases, the
                      initial staging and therapeutic management may even change.
                      Some FAPI radioligands may also be labelled with therapeutic
                      radionuclides for theranostic applications. It is thus
                      possible to treat certain metastatic cancers with FAPI
                      radioligand therapy (FAPI-RLT), which is generally well
                      tolerated with little toxicity. Recently, new FAPIs have
                      been developed with the particularity of having a higher
                      binding affinity the target, which further improves the
                      lesion detection rate on PET/CT and clinical outcomes
                      following FAPI-RLT. This review provides recent updates in
                      the clinical use of FAPI PET/CT and FAPI-RLT, and discusses
                      potential emergent applications, including in inflammation
                      imaging.},
      keywords     = {FAPI PET (Other) / FAPI radioligand therapy (Other) /
                      fibroblast activation protein inhibitor (Other) /
                      theranostics (Other)},
      cin          = {ED01},
      ddc          = {610},
      cid          = {I:(DE-He78)ED01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:39908453},
      doi          = {10.1093/bjr/tqaf020},
      url          = {https://inrepo02.dkfz.de/record/298581},
}